The research company will receive $11.7m for toxicology studies and an additional $2.6 m for pharmacology and pharmacokinetics studies which will be conducted through NCI’s Developmental Therapeutics Program.
SRI will evaluate the safety and efficacy of several potential treatments for cancer and other diseases of critical importance.
SRI Biosciences Division managing director Jon Mirsalis said the company’s support of NCI and its programs have led to numerous products for the treatment and prevention of cancer.
"The continuation of the NCI preclinical development service contracts extends important work SRI researchers do to advance drug discovery and development," Mirsalis added.